ArticleBiomedicines2021
Targeting of the Essential
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Antisense peptide nucleic acids targeting ribosomal protein genes: A novel strategy against carbapenem-resistantMolecular therapy. Nucleic acids · 2026Article
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Peptide Nucleic Acids (PNAs) in Antimicrobial Therapy: A Next Generation Strategy.International journal of molecular sciences · 2026Review
- Advances in peptide nucleic acid for targeting RNA and genomic DNA.Cell reports. Physical science · 2026Article
- Liposomes as delivery vectors for nucleic acid mimics intoFrontiers in bioengineering and biotechnology · 2026Article
- TargetingInternational journal of molecular sciences · 2025Article
- An antisense peptide-conjugated peptide nucleic acid (PPNA) for peptidoglycan recycling inhibition reduces AmpC hyperproduction and β-lactam resistance inMicrobiology spectrum · 2025Article
- ASOBIOTICS 2024: an interdisciplinary symposium on antisense-based programmable RNA antibiotics.RNA (New York, N.Y.) · 2025Article
- Exploring the Chemical Features and Biomedical Relevance of Cell-Penetrating Peptides.International journal of molecular sciences · 2024Review
- Evolution of Resistance against Ciprofloxacin, Tobramycin, and Trimethoprim/Sulfamethoxazole in the Environmental Opportunistic PathogenAntibiotics (Basel, Switzerland) · 2024Article
- Iron uptake pathway ofFrontiers in microbiology · 2024Article
- Selected strategies to fight pathogenic bacteria.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Is type III prostatitis also associated with bacterial infection?Frontiers in cellular and infection microbiology · 2023Article
- The Search for Antibacterial Inhibitors Targeting Cell Division Protein FtsZ at Its Nucleotide and Allosteric Binding Sites.Biomedicines · 2022Review
- Comprehensive analysis of PNA-based antisense antibiotics targeting various essential genes in uropathogenic Escherichia coli.Nucleic acids research · 2022Article
- Antisense Peptide Nucleic Acid-Diaminobutanoic Acid Dendron Conjugates with SbmA-Independent Antimicrobial Activity against Gram-Negative Bacteria.ACS infectious diseases · 2022Article
- Evaluation of accessible regions ofIranian journal of microbiology · 2021Article
- Oligonucleotides-Based Therapeutics.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Infections by carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.